Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/31859
Title: | Mosaicism in tuberous sclerosis complex: Lowering the threshold for clinical reporting. | Austin Authors: | Ye, Zimeng;Lin, Sufang;Zhao, Xia;Bennett, Mark F ;Brown, Natasha J;Wallis, Mathew J ;Gao, Xinyi;Sun, Li;Wu, Jiarui;Vedururu, Ravikiran;Witkowski, Tom ;Gardiner, Fiona;Stutterd, Chloe A ;Duan, Jing;Mullen, Saul A ;McGillivray, George;Bodek, Simon;Valente, Giulia M ;Reagan, Matthew;Yao, Yi;Li, Lin;Chen, Li;Boys, Amber;Adikari, Thiuni N;Cao, Dezhi;Hu, Zhanqi;Beshay, Victoria;Zhang, Victor W;Berkovic, Samuel F ;Scheffer, Ingrid E ;Liao, Jianxiang;Hildebrand, Michael S | Affiliation: | Epilepsy Research Centre Department of Neurology, Epilepsy Centre, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China. Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia. Austin Health AmCare Genomics Laboratory, Guangzhou, Guangdong Province, China. Molecular Diagnostic Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Victorian Clinical Genetics Services, Royal Children's Hospital, Parkville, Victoria, Australia. Department of Neurology, Epilepsy Centre, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China. Victorian Clinical Genetics Services, Royal Children's Hospital, Parkville, Victoria, Australia. Department of Medicine, Peninsula Health, Monash University, Frankston, Victoria, Australia. Molecular Diagnostic Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. AmCare Genomics Laboratory, Guangzhou, Guangdong Province, China. Department of Neurology, Epilepsy Centre, Shenzhen Children's Hospital, Shenzhen, Guangdong Province, China. The Florey Institute of Neuroscience and Mental Health |
Issue Date: | Dec-2022 | Date: | 2022 | Publication information: | Human Mutation 2022; 43(12) | Abstract: | Tuberous sclerosis complex (TSC) is a multi-system genetic disorder. Most patients have germline mutations in TSC1 or TSC2 but, 10%-15% patients do not have TSC1/TSC2 mutations detected on routine clinical genetic testing. We investigated the contribution of low-level mosaic TSC1/TSC2 mutations in unsolved sporadic patients and families with TSC. Thirty-one sporadic TSC patients negative on routine testing and eight families with suspected parental mosaicism were sequenced using deep panel sequencing followed by droplet digital polymerase chain reaction. Pathogenic variants were found in 22/31 (71%) unsolved sporadic patients, 16 were mosaic (median variant allele fraction [VAF] 6.8% in blood) and 6 had missed germline mutations. Parental mosaicism was detected in 5/8 families (median VAF 1% in blood). Clinical testing laboratories typically only report pathogenic variants with allele fractions above 10%. Our findings highlight the critical need to change laboratory practice by implementing higher sensitivity assays to improve diagnostic yield, inform patient management and guide reproductive counseling. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/31859 | DOI: | 10.1002/humu.24454 | ORCID: | 0000-0002-5578-9374 |
Journal: | Human Mutation | Start page: | 1956 | End page: | 1969 | PubMed URL: | 36030538 | ISSN: | 1098-1004 | Type: | Journal Article | Subjects: | high-depth sequencing mosaic mutations parental mosaicism tuberous sclerosis complex Tuberous Sclerosis/diagnosis Tuberous Sclerosis/genetics Tuberous Sclerosis/pathology Tuberous Sclerosis Complex 2 Protein/genetics Tuberous Sclerosis Complex 1 Protein/genetics Tumor Suppressor Proteins/genetics |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.